Catheter-related Bloodstream Infection (CRBSI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Catheter-related Bloodstream Infection (CRBSI) Market Outlook

Thelansis’s “Catheter-related Bloodstream Infection (CRBSI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Catheter-related Bloodstream Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Catheter-related Bloodstream Infection (CRBSI) Overview

Catheter-related bloodstream infection (CRBSI) refers to the presence of bacteremia originating from an intravenous catheter. It is a common, severe, and expensive complication of central venous catheterization and is the leading cause of nosocomial bacteremia. Intravascular catheters are vital in modern medical practices, being used in critically ill patients for various purposes such as administering fluids, blood products, medication, nutritional solutions, and monitoring hemodynamics. Among all medical devices, central venous catheters (CVCs) carry the highest risk of device-related infections and contribute significantly to morbidity and mortality. They are also the primary source of bacteremia and septicemia in hospitalized patients. Several potential risk factors contribute to the development of CRBSI, including underlying diseases, method and site of catheter insertion, duration of catheterization, and the purpose of catheterization. The use of intravascular catheters for parenteral nutrition increases the risk of CRBSI. The catheter itself can be involved in four different pathways leading to infection: colonization of the catheter tip and cutaneous tract by skin flora, colonization of the catheter lumen due to contamination, hematogenous seeding of the catheter from another infected site, and contamination of the catheter lumen with infusate. Gram-positive pathogens accounted for 64% of CRBSI cases, while Gram-negative pathogens accounted for 36%. The most common pathogens causing CRBSI were Staphylococcus aureus (40%), Pseudomonas aeruginosa (16%), coagulase-negative staphylococci (8%), Escherichia coli (8%), Klebsiella pneumoniae (8%), and Acinetobacter baumannii (4%). The choice of initial antibiotics for treating CRBSI depends on the severity of the patient's clinical condition, risk factors for infection, and the likely pathogens associated with the specific intravascular device.

• In the USA, the incidence of Catheter-Related Bloodstream Infections (CRBSI) ranges from 0.05 to 6.8 infections per 1000 catheter days.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: